NEFL and Wilson disease: The initial pilot study introducing this scale [53], subsequent validation studies [68] (100 patients with WD), and the inclusion of additional biomarkers like neurofilament light chains (sNfLs) (61 drug naïve patients with WD) [69] have underscored the reliability of this approach.